0001551986-20-000136.txt : 20200505
0001551986-20-000136.hdr.sgml : 20200505
20200505161856
ACCESSION NUMBER: 0001551986-20-000136
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200504
FILED AS OF DATE: 20200505
DATE AS OF CHANGE: 20200505
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Darvish Nissim
CENTRAL INDEX KEY: 0001793602
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
FILM NUMBER: 20849131
MAIL ADDRESS:
STREET 1: C/O INNOVATE BIOPHARMACEUTICALS, INC.
STREET 2: 8480 HONEYCUTT ROAD, SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001551986
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: 919-275-1933
MAIL ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: Monster Digital, Inc.
DATE OF NAME CHANGE: 20150930
FORMER COMPANY:
FORMER CONFORMED NAME: Tandon Digital, Inc.
DATE OF NAME CHANGE: 20120611
4
1
wf-form4_158870991773399.xml
FORM 4
X0306
4
2020-05-04
0
0001551986
INNOVATE BIOPHARMACEUTICALS, INC.
NMTR
0001793602
Darvish Nissim
C/O 9 METERS BIOPHARMA, INC.
8480 HONEYCUTT RD, STE 120
RALEIGH
NC
27615
1
0
1
0
Series A Convertible Preferred Stock
2020-05-04
4
P
0
67865
0
A
2020-05-04
Common stock
6786500.0
6786500
I
See Footnote
Series A Convertible Preferred Warrant
2020-05-04
4
P
0
67865
A
2020-05-04
2025-05-04
Common stock
6786500.0
6786500
I
See Footnote
The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date.
The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any.
The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis.
EX-24 Power of Attorney
/s/ Lorna A. Knick, as power of attorney
2020-05-04